ArriVent's ARR-217 ADC Shows 44.8% ORR in Late-Line CRC at ESMO 2026
AVBP has more than doubled off its 52-week low of $11.36 on elevated volume (3.0× avg).
Summary
ArriVent reported initial Phase 1 data for its CDH17-targeted ADC ARR-217, including a 44.8% objective response rate at the 6 mg/kg dose in pretreated colorectal cancer patients, and said the drug has moved into Phase 1b dose optimization.
Key Events · Product Development and Regulatory · AVBP
-
ARR-217 Phase 1 Data at ESMO
Initial Phase 1 results for CDH17-targeted ADC ARR-217 (MRG007) in gastrointestinal cancers were presented at ESMO Congress 2026, based on 123 heavily pretreated patients treated across six dose levels from 2 to 8 mg/kg, including 113 with colorectal cancer, as of an August 5, 2026 data cutoff.
-
44.8% ORR at 6 mg/kg
At the 6 mg/kg Q3W dose, ARR-217 produced a 44.8% (13/29) objective response rate in pretreated CRC patients and a 93.1% (27/29) disease control rate; at 4 mg/kg and higher the ORR was 34.2% (25/73) with 91.8% DCR.
-
Manageable Safety Profile
Most treatment-related adverse events were Grade 1/2; Grade 3 or higher TRAEs occurred in 30.1% (37/123) across all doses and 20.4% (10/49) at 6.0 mg/kg, with no Grade 5 TRAE and no ILD observed.
-
Phase 1b Dose Optimization Underway
ARR-217 has advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W, with further dose optimization data expected in 2027.
Analysis · AVBP · Life Sciences
With lead asset firmonertinib having failed its pivotal Phase 3 FURVENT trial on October 6, the pipeline story now rests on the ADCs. ARR-217 delivered a 44.8% objective response rate (13/29) at the 6 mg/kg dose in heavily pretreated colorectal cancer patients, with a 93.1% disease control rate and a manageable safety profile (20.4% Grade 3+ treatment-related events at that dose, no Grade 5 events or ILD). That is a credible early efficacy read for a CDH17-targeted ADC and supports the Phase 1b dose optimization already underway at 5 and 6 mg/kg. The caveat is that this is small, single-arm, early-stage data with a August 5, 2026 cutoff, and the next real readout is dose-optimization data expected in 2027 — so it rebuilds confidence in the pipeline without yet replacing the revenue base lost with firmonertinib.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVBP was trading at $23.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $11.36 to $35.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.